DISA (SGX:532) has entered into a non-binding agreement to acquire 50% of an operator of a rheumatism and arthritis specialist medical center, according to a Monday filing on the Singapore Exchange.
The SG$5.5 million proposed acquisition involves a cash payment of SG$3 million and SG$2.5 million in newly issued DISA shares, priced at either the prevailing market price or a minimum that will be determined later.
The target company, established in 2003, is Singapore's only heartland-based center specializing in arthritis and rheumatism care, with FY24 revenue of SG$7.6 million and EBITDA of SG$2.1 million.
Completion depends on due diligence, funding, and approvals, with the seller committing to a 10-year practitioner role and maintaining a 50% stake.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.